Molipaxin (Trazodone Hydrochloride)

Trazodone Hydrochloride, the active ingredient in Molipaxin, is a serotonin antagonist and reuptake inhibitor (SARI) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder and insomnia in adult patients.

GNH USA supplies Molipaxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality and regulatory compliance across EU and global markets. Molipaxin is manufactured under strict Good Manufacturing Practice (GMP) standards and distributed through a secure, temperature‑controlled logistics network.

Molipaxin (trazodone) acts on serotonergic pathways and is employed in the management of mood and sleep disorders. - Major depressive disorder: alleviates depressive symptoms and improves mood in adult patients. - Insomnia: promotes sleep onset and maintenance, reducing nighttime awakenings. - Depressive symptoms associated with chronic illness: helps improve mood and quality of life when depression coexists with other medical conditions.

Trazodone may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Dizziness: a sensation of light‑headedness or unsteadiness that may increase fall risk, especially when standing quickly. - Dry mouth: reduced salivation leading to throat discomfort and increased thirst, often manageable with hydration. - Drowsiness: pronounced sleepiness that can affect alertness and daily activities, particularly after the first doses. - Nausea: mild to moderate stomach upset or queasiness, sometimes accompanied by loss of appetite. - Headache: mild to moderate pain in the head, which may be intermittent or persistent. Serious or Rare Side Effects: - Priapism: prolonged, painful erection lasting more than four hours, requiring urgent medical treatment to prevent tissue damage. - Serotonin syndrome: a potentially life‑threatening condition marked by confusion, high fever, muscle rigidity, rapid heart rate, and tremor. - Severe hypotension: a marked drop in blood pressure that can cause fainting, dizziness, and in extreme cases, shock.

When prescribing Molipaxin, clinicians should consider several precautionary measures to ensure patient safety. - Assess cardiovascular status: monitor blood pressure and heart rate due to α₁‑adrenergic blockade. - Avoid abrupt discontinuation: taper the dose under medical supervision to reduce withdrawal symptoms. - Caution in hepatic impairment: dose adjustment may be required because of hepatic metabolism. - Avoid concurrent MAO inhibitors: risk of serotonin syndrome if combined with MAO‑I therapy. - Pregnancy and lactation: use only if potential benefits justify potential risks to the fetus or infant. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Trazodone can interact with other medicines, affecting its efficacy or safety profile. Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, triptans): increase risk of serotonin syndrome. - Carbamazepine: induces metabolism, reducing trazodone plasma levels. - Alcohol: enhances central nervous system depression and dizziness. Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect may require blood pressure monitoring. - CNS depressants (benzodiazepines, opioids): may increase sedation and respiratory depression. - CYP3A4 inhibitors (ketoconazole, erythromycin): may raise trazodone concentrations, adjust dose if needed.